皮肤性病诊疗学杂志2024，Vol.31Issue(5)：287-296,10.DOI:10.3969/j.issn.1674-8468.2024.05.001
系统性硬皮病靶向治疗研究进展
Advances in targeted therapies for systemic sclerosis
摘要
Abstract
Systemic sclerosis(SSc),as an immune-mediated chronic connective tissue dis-ease,is mainly characterized by fibrosis of multiple organs,including the skin and lungs.It is a rare disease,with a high incidence and mortality among rheumatic immune diseases.At present,there is no effective drug for the treatment of SSC.In recent years,it has been found that the in-teractions between T/B lymphocytes,fibroblasts,endothelial cells,and various pro-inflammatory and fibrotic signaling molecules play a crucial role in the occurrence and development of SSc.On this basis,a series of targeted drugs are currently being tested.CD20 monoclonal antibodies(Rit-uximab),IL-6 receptor antagonists(Tocilizumab),and multi-target tyrosine kinase inhibitors(Nintedanib)have been approved for the treatment of SSc or SSc-ILD by FDA.In addition,other targeted drugs such as Janus kinase inhibitors and various interleukin inhibitors have shown pre-liminary therapeutic potentials through clinical trials.This article reviews the research progress in targeted therapies for SSc by synthesizing the latest evidence from four aspects:targeting B lym-phocytes,T lymphocytes,vascular endothelial cells,and pro-inflammatory and fibrotic signaling molecules.关键词
系统性硬皮病/靶向治疗/生物制剂/小分子化合物Key words
systemic sclerosis/targeted therapy/biologic agents/small molecule com-pounds引用本文复制引用
肖嵘,刘佳倪..系统性硬皮病靶向治疗研究进展[J].皮肤性病诊疗学杂志,2024,31(5):287-296,10.基金项目
国家自然科学基金面上项目(82373486 （）
82073449) （）
国家自然科学基金青年项目(82304024 （）
82001738 （）
82003363 （）
82203932 （）
82203930) （）
湖南省研究生科研创新项目(CX20220343) （CX20220343）
